Mark Lackner's most recent trade in Zentalis Pharmaceuticals Inc was a trade of 335,907 Common Stock done . Disclosure was reported to the exchange on Feb. 3, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Zentalis Pharma Inc | Mark Lackner | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 335,907 | 527,224 | - | 0 | Common Stock | |
| Zentalis Pharma Inc | Mark Lackner | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 124,714 | 124,714 | - | - | Stock Option (Right to Buy) | |
| Zentalis Pharma Inc | Mark Lackner | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 1.71 per share. | 03 Feb 2025 | 14,368 | 512,856 | - | 1.7 | 24,591 | Common Stock |
| Zentalis Pharma Inc | Mark Lackner | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 3.12 per share. | 02 Jan 2025 | 4,411 | 191,317 | - | 3.1 | 13,762 | Common Stock |
| Zentalis Pharma Inc | Mark Lackner | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 141,000 | 141,000 | - | - | Stock Option (Right to Buy) | |
| Zentalis Pharma Inc | Mark Lackner | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 141,000 | 197,313 | - | 0 | Common Stock | |
| Zentalis Pharma Inc | Mark Lackner | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 11.54 per share. | 01 Feb 2024 | 1,585 | 195,728 | - | 11.5 | 18,291 | Common Stock |
| Zentalis Pharma Inc | Mark Lackner | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Zentalis Pharma Inc | Mark Lackner | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 40,000 | 56,313 | - | 0 | Common Stock |